Background Gastric cancer with lymphoid stroma (GCLS) is pathologically characterized by poorly developed tubular structures with a prominent lymphocytic infiltration. Its clinical and prognostic features differ in patients positive and negative for Epstein-Barr virus (EBV) infection. This study analyzed the expression of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and the density of tumor-infiltrating lymphocytes (TILs) including CD3+ and CD8+ T cells, as well as their prognostic significance in patients with GCLS. Methods The study included 58 patients with GCLS (29 EBV+ and 29 EBV−) who underwent curative resection. Expression of CD3, CD8, PD-1, and PD-L1 in tumor cells and TILs was analyzed using a quantitative multispectral imaging system (Opal™), with these results validated by immuno-histochemical assays for PD-L1 on whole slide sections. Results The proportion of tumors overexpressing PD-L1 (31.0 vs. 0%, P = 0.002), TIL density (4548 vs. 2631/mm 2 , P < 0.001), and intra-tumoral CD8+ T-cell density (2650 vs. 1060/mm 2 , P < 0.001) were significantly higher in EBV+ than in EBV− GCLS. In addition, CD8+/CD3+ T-cell ratio was higher in EBV+ than in EBV− GCLS (55.3 vs. 35.8%, P < 0.001). Lower TIL density, defined as < 1350/mm 2 , was a significant negative factor of survival. Conclusions Despite histopathological similarity, quantitative multispectral imaging revealed differences in the tumor immune micro-environment between EBV+ and EBV− GCLS, indicating that the underlying pathogenesis differs in these two disease entities. TIL density may be a prognostic marker in patients with GCLS.
Introduction
Gastric cancer with lymphoid stroma (GCLS) is a rare histologic subtype of gastric cancer distinguished by densely packed tumor cells with massive infiltration of lymphocytes into the tumor and surrounding stroma [1] [2] [3] . GCLS can be divided into two subtypes, consisting of tumors positive and negative for Epstein-Barr virus (EBV) infection, which are 1 3 histologically indistinguishable. Most GCLSs are positive for EBV infection (EBV+), as shown by EBV in situ hybridization (ISH). EBV+ GCLSs are predominantly located in the upper third of the stomach, show earlier onset and better prognosis than conventional gastric adenocarcinomas [4, 5] . In contrast, the clinical characteristics and prognosis of EBV− GCLS are comparable to those of conventional adenocarcinoma of the stomach [5] . Despite greater understanding of the clinicopathological characteristics of this disease, the mechanisms and/or factors underlying their carcinogenesis have not been determined.
Higher number of tumor-infiltrating lymphocytes (TILs) have been associated with better prognosis in several types of cancer [6] [7] [8] [9] . Tumors have, therefore, been classified by micro-environment-related parameters, such as Immunoscore, and the treatment of several types of cancer by adoptive T-cell transfer has been attempted [10] [11] [12] [13] . Also, EBV-associated gastric cancer (EBVaGC) frequently shows programmed cell death ligand-1 (PD-L1) overexpression and amplification of chromosome 9p, which contains the CD274, PDCD1LG2, and JAK2 genes [14] [15] [16] .
Considering that lymphocytes are heavily infiltrated in GCLS and that EBV+ tumors comprise the majority of GCLS, we reasoned that the distribution of immune cells (CD8+ and/or CD3+ T cells) and the immune checkpoint modulators such as programmed cell death-1 (PD-1) and PD-L1 may affect the clinical characteristics and prognosis of patients with GCLS. This study, therefore, analyzed PD-1 and PD-L1 expression, as well as intra-tumoral CD8+ and/ or CD3+ T-cell density, in GCLS using quantitative multispectral imaging (MSI), which enables simultaneous examination of six distinct markers. Further, this study assessed whether these factors have prognostic impact in patients with GCLS.
Methods

Study patients
This study retrospectively analyzed hematoxylin and eosin (H&E) stained slides of paraffin-embedded samples from 289 patients with GCLS who underwent gastric resection with curative intent in our center between 1998 and 2012, as previously described [5] . Only the 215 patients with GCLS component ≥ 70% were included in this study, 186 patients with EBV+ GCLS and 29 patients with EBV− GCLS. Twenty-nine EBV+ GCLS patients were randomly selected by simple random sampling using SAS software, version 9.1 (SAS Institute, Cary, NC, USA) for comparison with the 29 patients with EBV− GCLS ( Supplementary Fig. 1 ). After random selection, baseline characteristics and prognoses of the selected EBV+ GCLS patients (n = 29) were compared with those of non-selected EBV+ GCLS patients (n = 157). There was no significant difference in the baseline characteristics between selected and non-selected cases (Supplementary Table 1 ). Also, the 5-year survival rate (YSR) of selected patients did not significantly differ from 5-YSR of non-selected patients (96.4 vs. 96.1%, P = 0.608). The study protocol was approved by the Institutional Review Board of Asan Medical Center. (IRB No. 2017-0133).
Pathologic analysis
All cases of H&E slides were examined by two experienced gastrointestinal pathologists (YSP, HJK). For each patient, a single key slide was selected with the following criteria: (1) the highest GCLS proportion with the deepest tumor invasion, (2) well-defined tumor center and invasive margin, (3) well-defined tumor invasive margin and non-neoplastic tissue, and (4) no necrosis or hemorrhage (Fig. 1a, upper) . Identical whole-slide sections were used for immunohistochemical (IHC) staining, Opal™ staining, and EBV ISH.
EBV ISH
EBV ISH was performed using the Bench Mark XT autostainer (Ventana Medical Systems, Tucson, AZ, USA) and Ventana ISH iVIEW Blue Detection Kit (Ventana Medical Systems), according to the manufacturer's instructions. Briefly, 4-µm-thick whole-slide sections, obtained with a microtome, were transferred onto silanized slides and allowed to dry for 10 min at room temperature, followed by 20 min in an incubator at 65 °C. The sections were treated with protease Z for 8 min, and incubated for 2 h with EBER probe (800-2842, Ventana Medical Systems) in the autoimmunostainer. Dark blue/purple at the site of hybridization (nucleus) was interpreted as positive for EBV (Fig. 1a,  lower) .
IHC staining and evaluation
Fifty-eight cases of key formalin-fixed paraffin-embedded (FFPE) blocks were immunohistochemically stained with antibody to PD-L1 (rabbit monoclonal E1L3 N, 1/100; Cell Signaling, Danvers, MA, USA) using the Bench Mark XT automatic immunostaining device with an OptiView DAB IHC Detection Kit (Ventana Medical Systems) according to the manufacturer's instructions. Serial 4-μm-thick sections were transferred onto silanized slides and allowed to dry for 10 min at room temperature, followed by 20 min in an incubator at 65 °C, subjected to heat-induced epitope retrieval using Cell Conditioning 1 (CC1) buffer for 32 min, and incubated for 16 min with anti-PD-L1 antibody in the autoimmunostainer. Results of immunostaining were independently evaluated by two pathologists (HJK, HJJ), who were blinded to clinical outcomes. PD-L1 expression was assessed in tumor cells and intra-tumoral lymphocytes. PD-L1 expression in tumor and immune cells was scored by the Immunoreactivity Scoring System (IRS), based on the percentage of stained cells and staining intensity (Supplementary Table 2 ) [16] . PD-L1 expression in immune cells was categorized by the percentage of PD-L1 positive cells.
Multiplex immunofluorescence staining
Four-micrometer-thick whole-slide sections, obtained with a microtome, were transferred onto plus charged slides, followed by multiplex immunofluorescence staining with a Leica Bond Rx™ Automated Stainer (Leica Biosystems, Newcastle, UK). Briefly, the slides were baked for 30 min and dewaxed with Leica Bond Dewax solution (Cat #AR9222, Leica Biosystems, Milton Keynes, UK), followed by antigen retrieval with Bond Epitope Retrieval 2 (Cat #AR9640, Leica Biosystems, Milton Keynes, UK) in a pH 9.0 solution for 30 min.
Multiplex immunofluorescence staining was performed using the Opal™ 7-color Automation IHC Kit (Perkin Elmer, Waltham, MA, USA). PD-1 (ab137132, AbCam, Cambridge, MA, USA) expression was visualized by Opal™ 690 tyramide signal amplification (TSA) Plus (dilution, 1:300); PD-L1 (13684, CST, Danvers, MA, USA) by Opal™ 650 TSA Plus (dilution, 1:150); Each section was subjected to five sequential rounds of staining, each including a protein block with PKI blocking/antibody diluent, followed by incubation with primary antibody and corresponding secondary horseradish peroxidase-conjugated polymer using Opal™ Polymer HRP Ms + Rb kit (Perkin Elmer, Waltham, MA, USA). Each horseradish peroxidase-conjugated polymer mediated the covalent binding of a different fluorophore using TSA. This covalent reaction was followed by additional antigen retrieval with Bond Epitope Retrieval 1 (Cat #AR9961, Leica Biosystems, Milton Keynes, UK) for 20 min to remove bound antibodies before the next step in the sequence. After five sequential reactions, sections were counterstained with DAPI and coverslipped using HIGHDEF ® IHC fluoromount (Enzo Life Sciences, Farmingdale, NY, USA).
Multispectral imaging
Multiplex stained slides were scanned using the Vectra 
Spectral unmixing
A spectral library containing the emitting spectral peaks of all fluorophores was created using inForm 2.2.1 image analysis software (Perkin Elmer, Wellesley, MA, USA), based on multispectral images obtained from single stained slides for each marker and associated fluorophore (Fig. 1b ). This spectral library was used to separate each multispectral image cube into its individual components (spectral unmixing), allowing for the color-based identification of all six markers of interest in a single image using inForm 2.2.1 image analysis software (Fig. 1c) . Quantitative measurement of the area occupied by the inflammatory cells in the scanned image was also performed with the inForm 2.2.1 software. All spectrally unmixed and segmented images were analyzed using inForm and Spotfire™ software (TIBCO Software Inc., Palo Alto, CA, USA).
Analysis with Spotfire™ software and compartmentalization of the samples
The data obtained from inForm were sent to Spotfire™ software and threshold for positivity of each factor was determined based on IHC scoring methods (Fig. 1d) . Scores indicating positivity were > 2.8 for CK, > 4.6 for CD3, > 6.0 for CD8, > 1.5 for PD-1, and > 10.0 for PD-L1. All cells in each slide were designated as positive or negative for each antibody, and the data were categorized and exported to an xls file for analysis. For the analysis of percentage or density of cells, whole tumor area was divided into multiple fields, which is defined as an equal rectangular unit composed of 1,349,376 pixels (Fig. 1e, left) . Also, whole tumor was dichotomized into the tumor center and invasive margins and were evaluated for each component (Fig. 1e, right) . A mean of 129.7 ± 86.8 fields was analyzed in total tumor area, 119.4 ± 64.6 from EBV− GCLS tumors and 139.9 ± 104.6 from EBV+ GCLS tumors (P = 0.373). Tumor centers were analyzed in mean 113.1 ± 83.0 fields, 101.8 ± 60.6 from EBV− GCLS and 124.5 ± 100.5 from EBV+ GCLS tumors (P = 0.303), and invasive margins in mean 16.5 ± 7.3 fields, 17.6 ± 7.5 from EBV− GCLS and 15.4 ± 7.0 from EBV+ GCLS tumors (P = 0.261). The formula used to convert cell density from cell number per field to cell number per mm 2 is as follows: cell number per mm 2 = cell number per field/0.36.
Statistical analysis
Continuous variables and proportions were compared using the independent T, Mann-Whitney U, Chi-square, or Fisher's exact test, as appropriate. To assess the association between data, Pearson's correlation coefficient was used. Receive operating characteristic (ROC) curve analysis was used to determine the appropriate cutoff of TIL density affecting survival. The highest Youden index (sensitivity + specificity − 1) was calculated to determine the best cutoff value. The probability of overall survival (OS) and disease-free survival (DFS) was estimated using the Kaplan-Meier method and compared using Cox proportional hazards regression models. A backward elimination approach involving candidate variables with P ≤ 0.10 on univariate analysis was used for multivariable analysis. Two-tailed P values < 0.05 were considered statistically significant. All statistical analyses were performed using SPSS 22.0 software (SPSS Inc., Chicago, IL, USA).
Results
Clinicopathologic characteristics of the patients
The baseline demographic and clinical characteristics of the selected patients are shown in Table 1 . Patients with EBV− GCLS were older, and lesions were more frequently located in the lower third of the stomach. Gender, stage, and lymphovascular and perineural invasion status did not differ between the two groups. Patients with EBV− GCLS showed a significantly lower 5-YSR than patients with EBV+ GCLS (79.4 vs. 96.4%, P = 0.032, Supplementary  Fig. 2 ). Subgroup analysis with stage II or III GCLS patients also showed worse prognosis in EBV− GCLS (5-YSR 63.9 vs. 94.4%, P = 0.030). DFS between EBV− GCLS and EBV+ GCLS were not statistically significant (5-YSR 79.4 vs. 96.4%, P = 0.059).
We then analyzed the baseline characteristics and prognoses of whole GCLS population (n = 215; 29 EBV− GCLS and 186 EBV+ GCLS) to determine whether the selected patients could be representative for whole GCLS population. Indeed, the baseline characteristics of the whole GCLS population were well-reflected by selected patients (Supplementary Table 3 ). 5-YSR of EBV− GCLS group was also lower than EBV+ GCLS group in whole GCLS population (79.4 vs. 96.2%, P = 0.003). Further, PD-L1 overexpression, defined as ≥ 25% PD-L1 positive cells, was significantly more frequent in EBV+ GCLS than in EBV− GCLS (31.0 vs. 0%, P = 0.002; Fig. 2a ). Dichotomization into tumor centers and invasive margins showed that PD-L1 overexpression was significantly more frequent in the center of EBV+ GCLS than of EBV− GCLS (27.6 vs. 0%, P = 0.004; Fig. 2b ), but that the difference was not significant at the invasive margins (17.2 vs. 10.3%, P = 0.706; Fig. 2c ). Similar findings were observed by IHC, with higher IRS score in EBV+ GCLS than in EBV− GCLS (3.2 ± 2.0 vs. 1.9 ± 1.7, P = 0.007). In addition, PD-L1 overexpression, defined as IRS ≥ 6, being significantly more frequent in EBV+ GCLS than in EBV− GCLS (20.7 vs. 0%, P = 0.023; Fig. 2d ). Analysis of concordance between the two methods for detection of PD-L1 overexpression showed a good strength of agreement (kappa agreement coefficient of 0.772). We also investigated whether lymphocyte PD-L1 positivity differed in EBV+ GCLS and EBV− GCLS. Intra-tumoral PD-L1+ lymphocytes, as determined by IRS score ≥ 2, were significantly more frequent in EBV+ GCLS than in EBV− GCLS (51.7 vs. 17.2%, P = 0.006; Fig. 2e ). 
Expression of PD-L1 in EBV+ GCLS and EBV− GCLS
TIL quantity and infiltration pattern in EBV+ GCLS and EBV− GCLS
TILs have been associated with favorable clinical outcomes and clinical response in various solid tumors. We, therefore, assessed the density of TILs using CD3+ T cell counts in GCLS. CD8+ T cell, which is known to play a central role in adaptive immune resistance associated with PD-L1 upregulation via type II interferon secretion, were also quantified. We found that CD3+ T-cell density was significantly higher in whole tumors (4547.6 ± 1997.9 vs. 2631.3 ± 1879.2/mm 2 , P < 0.001; Fig. 3a ), tumor centers (4478.8 ± 1941.1 vs. 2586.6 ± 1911.2/mm 2 , P < 0.001; Fig. 3b) , and invasive margins (5050.5 ± 2655.8 vs. 3126.4 ± 2963.6/mm 2 , P = 0.012; Fig. 3c ) of EBV+ GCLS than of EBV− GCLS samples. Similar results were observed for CD8+ T-cell density, which was significantly higher in whole tumors (2650.1 ± 1621.0 vs. 1060.0 ± 1066.6/mm 2 , P < 0.001; Fig. 3d Fig. 3f ] of EBV+ GCLS than of EBV− GCLS samples. In addition, CD8+/CD3+ T cell ratios were significantly higher in whole tumors (55.3 vs. 35.8%, P < 0.001; Fig. 3g ), tumor centers (55.9 vs. 34.9%, P < 0.001; Fig. 3h) , and invasive margins (53.5 vs. 38.8%, P = 0.002; Fig. 3i ) of EBV+ GCLS than of EBV− GCLS samples.
Effects of EBV infection and compartment on PD-L1+ TIL quantity and distribution pattern
Median PD-L1+ CD3+ T-cell densities were significantly higher in whole tumors [513.8 (IQR, 107.7-1163.6) vs. 
Effect of EBV infection on PD-1+ CD8+ intra-tumoral T-cell density
We further assessed whether PD-1 positive T-cell density differed in EBV+ and EBV− GCLS samples. PD-1+ CD8+ T-cell density was significantly higher in whole tumors [522. 2 , P = 0.019; Supplementary  Fig. 3c ] of EBV+ GCLS than of EBV− GCLS samples. However, the PD-1+ CD3+ T-cell density in whole tumors of EBV+ GCLS and EBV− GCLS samples did not differ significantly (1277.7 ± 1044.3 vs. 833.8 ± 631.4/mm 2 , P = 0.055; Supplementary Fig. 3d ). 
Correlation between PD-L1+ tumor cell proportion and PD-L1+ CD8+ T-cell density
Correlation analyses were performed to determine the relationships of PD-L1+ tumor cell proportion with TIL density and PD-L1 status. When assessed in all patients (n = 58), the proportion of PD-L1+ tumor cells showed significant positive correlations with PD-L1+ CD3+ T-cell density (R = 0.682, P < 0.001; Supplementary Fig. 4a ) and PD-L1+ CD8+ T-cell density (R = 0.694, P < 0.001; Supplementary Fig. 4b ). In addition, we observed a significant correlation between the densities of PD-L1+ CD8+ and PD-1+ CD8+ T-cells (R = 0.651, P < 0.001; Supplementary Fig. 4c) , with this correlation being stronger in EBV− GCLS (R = 0.826, P < 0.001) than in EBV+ GCLS (R = 0.576, P = 0.001).
Prognostic impact of TIL density in GCLS patient survival
Finally, we assessed whether tumor PD-L1 overexpression or TIL density are prognostic factors in GCLS. Using the Youden index, we calculated that a cutoff of 1350/mm 2 represented the point with the largest area under curve for patient survival. The 5-YSR was significantly higher in patients with a TIL density ≥ 1350/mm 2 than in those with a TIL density < 1350/mm 2 (92.8 vs. 64.8%, P = 0.001; Fig. 5 ). In contrast, 5-YSR in the two groups was independent of Univariate analysis of factors such as TIL density and tumor PD-L1 overexpression, as well as factors reported prognostic in patients with GCLS, including age, tumor stage, and presence of lymphovascular and perineural invasion, showed that advanced tumor stage and TIL density < 1350/mm 2 were significant negative predictors of OS. In the multivariate analysis, tumor stage III or IV (P = 0.02) and TIL density < 1350/mm 2 (P = 0.04) remained significant negative predictors of OS (Table 2) . Further, subgroup analyses were performed to assess whether TIL density is a prognostic factor in EBV− GCLS or EBV+ GCLS subgroup, respectively. Among EBV− GCLS patients (n = 29), the 5-YSR of patients with TIL density < 1350/mm 2 was significantly lower than that of patients with TIL density ≥ 1350/ mm 2 (60.0 vs. 87.7%, P = 0.018). There was no significant difference in survival of the patients according to TIL density classification in EBV+ GCLS due to small number of death cases (P = 0.847).
Discussion
This study showed that tumor PD-L1 overexpression and TIL infiltration profiles differ in GCLS with and without EBV infection. Intra-tumoral TIL density < 1350/mm 2 was a significant negative prognostic factor, along with advanced tumor stage.
Both B-and T-lymphocytes express PD-L1 and PD-1 [17, 18] . PD-1 expression on activated T-lymphocytes may lead to PD-L1 expression on tumor cells. Interactions between tumor PD-L1 and lymphocyte PD-1 may result in the exhaustion of T cells and constitute a mechanism by which tumor cells evade immune surveillance. Patients with these tumors may, therefore, benefit from a blockade of PD-1 or PD-L1 [19] [20] [21] [22] .
The effects of PD-L1 expression and TIL density on the prognosis of patients with gastric cancer have been found to differ among studies. For example, a Japanese study of 105 patients with stage II and III gastric cancer who underwent curative gastrectomy showed that OS was poorer in patients positive than negative for PD-L1. Although their EBV status was not reported, 53 of these patients had undifferentiated tumors, suggesting that some may have had GCLS [23] . In contrast, a study of 451 Caucasian patients with gastric cancer showed that high PD-L1/PD-1 expression was associated with better patient outcomes [16] . However, only 20 (4.4%) of these patients were positive for EBV, resulting in limited information on PD-L1 expression in patients with GCLS. A study of PD-L1 expression and CD8+ T-cell density in 34 patients with gastric cancer in the proximal stomach and gastroesophageal junction found that, although 32 (94%) were negative for EBV ISH, four (12%) tumors showed membranous PD-L1 expression [24] . In addition, increased CD8+ T-cell count was associated with increased PD-L1 expression, which negatively correlated with patient survival.
The result in the current study showed that PD-L1 overexpression was more frequent in patients with EBV+ GCLS than with EBV− GCLS. However, PD-L1 overexpression status was not associated with patient prognosis. This unique pattern and implication of PD-L1 expression in GCLS may be interpreted in several ways. First, the reasons for PD-L1 overexpression may vary in EBV+ GCLS. Although the only GCLSs containing ≥ 25% PD-L1-positive tumor cells were EBV+ , some EBV+ GCLSs showed no evidence of PD-L1 production either by MSI and/or IHC, which led to heterogeneity in PD-L1 expression of this group. PD-L1 overexpression by some of these tumors may be due to amplification of chromosome 9p, which harbors the gene coding PD-L1 [14] . PD-L1 expression may also be induced in response to pro-inflammatory cytokines and IFN-γ released by TILs, via activation of the JAK-STAT pathway and IRF1 [25, 26] . TILs are strongly associated with local PD-L1 expression in melanoma [27] , suggesting that PD-L1 overexpression in EBV+ GCLS may be related to their higher TIL density. Further, because epithelial and cancer cells can produce type I interferons in response to various stimuli [28, 29] , EBV+ GCLS tumor cells may produce interferons that activate PD-L1 in both tumor cells and lymphocytes [30] . Indeed, we observed a positive correlation between tumor PD-L1 and TIL PD-L1 expression, suggesting that interferon production in these patients affected both tumor and lymphocyte PD-L1 expression. The data in the current study may warrant further investigation focusing on the role of interferons and its downstream signaling components such as JAK/STAT, IRF9 or interferon stimulated genes as possible therapeutic targets for EBV+ GCLS [31] [32] [33] .
TIL density has been associated with a favorable prognosis in patients with gastric and other types of cancer [34] [35] [36] . In the present study, TIL density clearly differed in the EBV+ GCLS and EBV− GCLS groups, with the cutoff of 1350/mm 2 as TIL density affecting survival of the GCLS patients. We also tried to assess the quantity of TILs by measuring the area occupied by the inflammatory cells in the scanned image. Although the proportion of TIL area in patients with a TIL density ≥ 1350/mm 2 was larger than that in patients with a TIL density < 1350/mm 2 , statistical significance was not reached (62.9 ± 15.0 vs. 46.3 ± 26.5%, P = 0.10). We, therefore, suggest that TIL density measurement may be a more reliable modality in assessing the influence of TILs over eyeball measuring under microscopy or TIL area calculation.
It is unclear why relatively fewer T cells were recruited in EBV− GCLS, and whether the difference was due to a difference in their underlying pathogenesis. Microsatellite instability subtypes were reported to be associated with EBV− GCLS, making this association a subject of further investigation [15, 34] .
The limitations of this study include its retrospective nature and the relatively small number of patients. Some of the factors regarded as insignificant in this study may show significant differences in larger patient populations. Moreover, as all of our patients were Asian, the results of the current study may be limited to Asian populations, suggesting a need to assess these phenotypes in other ethnicities. To our knowledge, however, this is the first study to identify an as-yet-unknown factor associated with better prognosis in patients with EBV+ GCLS than with EBV− GCLS [37] . In addition, this study maximized the use of the MSI technique, which can simultaneously analyze cells positive for multiple markers and examine whole section slides, thereby enabling an overview of the whole landscape of tumor and immune cell populations with precision. The results of the current study provide important clues in understanding and developing treatment strategies for a rare group of patients with GCLS.
In conclusion, tumor PD-L1 overexpression and TIL infiltration profiles differ in GCLSs positive and negative for EBV infection. Intra-tumoral TIL density may serve as a prognostic marker in patients with GCLS.
